We are proud to announce that our product autologous adult bone marrow-derived non-expanded CD133+ haematopoietic stem cells (IGX1) was granted the Orphan Drug Designation (ODD) on March 15th 2017 by the European Medicines Agency (EMA). The product is aimed at the treatment of patients with the Asherman’s syndrome (AS), a srare disease defined by the […]
Blog
IGENOMIX receives EMA Orphan Drug Designation for its product indicated for Asherman’s Syndrome with Asphalion support
19
Jun
Jun